Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors

A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Malignant Tumors

The purpose of this study is to assess the safety and tolerability of BMS-663513 in subjects with advanced and/or metastatic malignant tumors.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Subjects with previously treated advanced malignant solid tumor
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
• For certain subjects, willing and able to provide pre-treatment tumor sample

Exclusion Criteria:

• Known or suspected central nervous system metastases or central nervous system as the only source of disease
• Other concomitant malignancies (with some exceptions per protocol)
• Active, known or suspected autoimmune disease